ARCT-032 (LUNAR®-CFTR) Improves Mucociliary Clearance in CF Ferrets

Xiaoming Liu, Meihui Luo, Guy Snow, Shahab Fakhari, Yihua Pei, Shuang Wu, Jia Ma, Douglas J. Bartels, Sourabh Shukla, Stefen A. Boehme, David E. Geller, John F. Engelhardt Arcturus Therapeutics and University of Iowa






mRNA Replacement Therapy


LUNAR®-CFTR (ARCT-032)



Cargo: Optimized hCFTR mRNA




Delivery vehicle: LUNAR[®] Lipid Nanoparticles




Delivery format: Aerosol

- Arcturus Therapeutics has developed mutation-agnostic mRNA treatment for CF lung disease
- ARCT-032 is currently being evaluated in a Phase 1 clinical trial

Epithelial Cell Types in Airways




CF Ferret Models at University of Iowa



Science Translational Medicine 2019 Human Gene Therapy 2022

LUNAR® Mediated Delivery of mRNA Payloads to Ferret ALI Cultures



LUNAR® Mediated Delivery of mRNA Payloads to Ferret Airways

LUNAR®




En Face Trachea


Cre mRNA +


Intralobar Airways

Vehicle **EGFP Tomato**













LUNAR®-CFTR and LUNAR®-tdTomato Delivery to Ferret Airways




LUNAR® Platform Targets Ciliated Cells












Pulmonary Ionocytes in the Proximal Airway



LUNAR® Platform Predominantly Targets Non-Ionocytes in the Ferret Proximal Airways





LUNAR®-Cre Transfection in ROSA-TG Ferrets




LUNAR® platform efficiently delivered mRNA payloads to multiple epithelial cell types including ciliated cells and some ionocytes in ferret airways.

Mucociliary Clearance (MCC) Endpoints in CF Ferrets









Airway clearance in the CF ferret model is CFTR-dependent.


ARCT-032 (LUNAR®-hCFTR) Improved MCC in CF Ferrets


- G551D ferrets were removed from VX-770 to achieve a MCC defect (20-40% of WT)
- MCC evaluated 24 hr post-dosing with LUNAR®-hCFTR or LUNAR®-TdTomato





ARCT-032 (LUNAR®-hCFTR) Improved MCC in CF Ferrets





Conclusions

- LUNAR® platform demonstrates efficient delivery of mRNA payloads and transfection in various cell types in ferret airways.
- ARCT-032 (LUNAR®-CFTR) improved CFTR activity in CF ferret model as demonstrated by significantly improved MCC.
- These in vivo results complement findings from in vitro studies in human bronchial epithelial cells (HBEs) derived from CF patients where ARCT-032 restored CFTR-mediated chloride conductance.
- ARCT-032 is currently being studied in a Phase 1 trial in healthy volunteers and adults with CF.